Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00442936
First received: February 28, 2007
Last updated: July 31, 2014
Last verified: July 2014

February 28, 2007
July 31, 2014
February 2007
October 2007   (final data collection date for primary outcome measure)
  • Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose [ Time Frame: 2 hours post-dose ] [ Designated as safety issue: No ]
    Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PF at 2 hours post-dose is defined as a decrease from a moderate or severe migraine headache (Grade 2 or 3) at baseline to no pain (Grade 0) at 2 hours post-dose.
  • Number of Participants With Pain Relief (PR) at 2 Hours Post-Dose [ Time Frame: 2 hours post-dose ] [ Designated as safety issue: No ]
    Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PR at 2 hours post-dose is defined as a shift from a moderate or severe migraine headache (Grade 2 or 3) at baseline to mild or no pain (Grade 1 or 0) at 2 hours post-dose.
  • Number of Participants With Absence of Photophobia at 2 Hours Post-Dose [ Time Frame: 2 hours post-dose ] [ Designated as safety issue: No ]
    Participants were asked if they experienced any sensitivity to light. The number of participants who experienced no photophobia (sensitivity to light) at 2 hours post-dose was determined.
  • Number of Participants With Absence of Phonophobia at 2 Hours Post-Dose [ Time Frame: 2 hours post-dose ] [ Designated as safety issue: No ]
    Participants were asked if they experienced any sensitivity to sound. The number of participants who experienced no phonophobia (sensitivity to sound) at 2 hours post-dose was determined.
  • Number of Participants With Absence of Nausea at 2 Hours Post-Dose [ Time Frame: 2 hours post-dose ] [ Designated as safety issue: No ]
    Participants were asked if they experienced any nausea. The number of participants who experienced no nausea at 2 hours post-dose was determined.
  • Number of Participants Who Experience At Least One Adverse Event (AE) [ Time Frame: Up to 14 days after last dose of study drug ] [ Designated as safety issue: Yes ]
    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for occurrence AEs for up to 14 days after last dose study drug. Participants who took both active and placebo study drug were counted in the active group.
  • Number of Participants Who Discontinue Study Drug Due to an AE [ Time Frame: Up to 48 hours after first dose of study drug ] [ Designated as safety issue: Yes ]
    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants who took both active and placebo study drug were counted in the active group.
Not Provided
Complete list of historical versions of study NCT00442936 on ClinicalTrials.gov Archive Site
  • Number of Participants With Sustained Pain Freedom (SPF) From 2 to 24 Hours Post-Dose [ Time Frame: 2 to 24 hours post-dose ] [ Designated as safety issue: No ]
    SPF is defined as PF at 2 hours post-dose with no return of mild/moderate/severe headache through 24 hours post-dose, and with no administration of either the optional second dose of study drug or any rescue medication between 2 and 24 hours post-dose.
  • Number of Participants With Total Migraine Freedom (TMF) at 2 Hours Post-Dose [ Time Frame: 2 hours post-dose ] [ Designated as safety issue: No ]
    TMF at 2 hours post-dose is defined as PF at 2 hours post-dose without any of the following migraine-related symptoms: phonophobia, photophobia, nausea or vomiting at 2 hours post-dose.
  • Number of Participants With Total Migraine Freedom (TMF) at 2 to 24 Hours Post-Dose [ Time Frame: 2 to 24 hours post-dose ] [ Designated as safety issue: No ]
    TMF at 2 to 24 hours post-dose is defined as TMF at 2 hours post-dose with no administration of either the optional second dose of study drug or any rescue medication between 2 and 24 hours post-dose, no return of mild/moderate/severe headache within 24 hours and no presence of phonophobia, photophobia, nausea or vomiting within 24 hours post-dose.
Not Provided
Not Provided
Not Provided
 
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura

The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine. This study was conducted as a "triple-dummy" design; for each dose of study drug, participants each received 3 forms of study drug (2 capsules of active and/or placebo and 1 tablet of active and/or placebo) and were instructed to take one of each form of study drug at dosing time.

The primary hypotheses of this study are that telcagepant is superior to placebo in Pain Freedom at 2 Hours Post-Dose, Pain Relief at 2 Hours Post-Dose, Absence of Photophobia at 2 Hours Post-Dose, Absence of Phonophobia at 2 Hours Post-Dose and Absence of Nausea at 2 Hours Post-Dose.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Migraine
  • Drug: Telcagepant potassium 150 mg
    Telcagepant 150 mg liquid-filled soft gel capsules
  • Drug: Telcagepant potassium 300 mg
    Telcagepant 300 mg liquid-filled soft gel capsules
  • Drug: Zolmitriptan 5 mg
    Zolmitriptan 5 mg tablets
  • Drug: Placebo to telcagepant 150 mg
    Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
  • Drug: Placebo to tecagepant 300 mg
    Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
  • Drug: Placebo to zolmitriptan 5 mg
    Placebo to match zolmitriptan 5 mg tablets
  • Drug: Rescue medication
    If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
  • Experimental: Telcagepant 150 mg
    Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
    Interventions:
    • Drug: Telcagepant potassium 150 mg
    • Drug: Placebo to tecagepant 300 mg
    • Drug: Placebo to zolmitriptan 5 mg
    • Drug: Rescue medication
  • Experimental: Telcagepant 300 mg
    Participants receive telcagepant 300 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 300 mg or placebo) or one dose of non-study rescue medication.
    Interventions:
    • Drug: Telcagepant potassium 300 mg
    • Drug: Placebo to telcagepant 150 mg
    • Drug: Placebo to zolmitriptan 5 mg
    • Drug: Rescue medication
  • Active Comparator: Zolmitriptan 5 mg
    Participants receive zolmitriptan 5 mg tablets, one tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
    Interventions:
    • Drug: Zolmitriptan 5 mg
    • Drug: Placebo to telcagepant 150 mg
    • Drug: Placebo to tecagepant 300 mg
    • Drug: Rescue medication
  • Placebo Comparator: Placebo
    Participants receive placebo matching capsules or tablets, one capsule or tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
    Interventions:
    • Drug: Placebo to telcagepant 150 mg
    • Drug: Placebo to tecagepant 300 mg
    • Drug: Placebo to zolmitriptan 5 mg
    • Drug: Rescue medication

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1380
October 2007
October 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has at least 1 year history of migraine (with or without aura)
  • Females of child bearing potential must use acceptable contraception throughout trial.

Exclusion Criteria:

  • Is pregnant/breast-feeding (or is a female expecting to conceive during study period)
  • Has history or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency virus (HIV) disease
  • Has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)
  • Has a history of gastric, or small intestinal surgery, or has a disease that causes malabsorption
  • Has a history of cancer within the last 5 years.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00442936
0974-011, MK-0974-011, 2006_525
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP